AjaiChariMD
Oncology • San Francisco, CAHematologic Oncology
Professor of Clinical Medicine, UCSF Director Multiple Myeloma Program
Overview of Dr. Chari
Dr. Ajai Chari is an oncologist in San Francisco, CA. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 18 years. Dr. Chari accepts several types of health insurance, listed below. He has more than 100 publications and over 500 citings.
Office
400 Parnassus Ave
Box 0324
San Francisco, CA 94143- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999
Certifications & Licensure
FL State Medical License 2022 - Present
CA State Medical License 2023 - 2025
NY State Medical License 2000 - 2024
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma Start of enrollment: 2006 Feb 01
- Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
- Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Start of enrollment: 2012 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
- Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, David G Coffey, Ajai Chari, Su...> ;Journal for Immunotherapy of Cancer. 2024 Apr 12
- Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Bad...> ;British Journal of Haematology. 2024 Mar 19
- Join now to see all
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patie...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Authored Content
- Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016
Press Mentions
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MDJanuary 31st, 2023- An Antibody Successfully Treats over 70% of Multiple Myeloma Patients in TrialDecember 26th, 2022
- New Cancer Drug Achieves 73% Response Rate in PatientsDecember 12th, 2022
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
